DGS Capital Management LLC Has $1.23 Million Stock Holdings in Novartis AG (NYSE:NVS)

DGS Capital Management LLC increased its position in Novartis AG (NYSE:NVS) by 18.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,601 shares of the company’s stock after buying an additional 1,918 shares during the quarter. DGS Capital Management LLC’s holdings in Novartis were worth $1,226,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also added to or reduced their stakes in NVS. Steigerwald Gordon & Koch Inc. raised its position in Novartis by 4.8% during the 3rd quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company’s stock worth $241,000 after purchasing an additional 95 shares during the last quarter. Centaurus Financial Inc. lifted its stake in shares of Novartis by 1.7% in the third quarter. Centaurus Financial Inc. now owns 5,728 shares of the company’s stock worth $659,000 after acquiring an additional 98 shares during the period. FLC Capital Advisors boosted its holdings in Novartis by 4.4% in the third quarter. FLC Capital Advisors now owns 2,366 shares of the company’s stock valued at $272,000 after acquiring an additional 100 shares during the last quarter. Clear Harbor Asset Management LLC increased its position in Novartis by 2.3% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company’s stock valued at $509,000 after purchasing an additional 100 shares during the period. Finally, Allen Wealth Management LLC raised its stake in Novartis by 1.8% during the third quarter. Allen Wealth Management LLC now owns 5,788 shares of the company’s stock worth $666,000 after buying an additional 100 shares during the last quarter. 13.12% of the stock is currently owned by institutional investors and hedge funds.

Novartis Stock Down 0.1 %

NVS stock opened at $99.93 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. The stock’s 50 day moving average is $100.15 and its 200-day moving average is $108.75. Novartis AG has a twelve month low of $92.35 and a twelve month high of $120.92. The firm has a market capitalization of $204.25 billion, a PE ratio of 11.61, a P/E/G ratio of 1.42 and a beta of 0.57.

Novartis (NYSE:NVS) last posted its earnings results on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.94 by $0.12. The firm had revenue of $12.82 billion for the quarter, compared to analysts’ expectations of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same quarter last year, the firm earned $1.74 EPS. Sell-side analysts expect that Novartis AG will post 7.62 EPS for the current fiscal year.

Analysts Set New Price Targets

NVS has been the subject of a number of recent analyst reports. HSBC downgraded Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. BMO Capital Markets lifted their price target on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a research note on Wednesday, October 30th. Finally, Erste Group Bank reaffirmed a “hold” rating on shares of Novartis in a research report on Tuesday, November 19th. Two investment analysts have rated the stock with a sell rating and six have given a hold rating to the company’s stock. According to data from MarketBeat.com, Novartis has a consensus rating of “Hold” and an average price target of $123.38.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.